EUCTR2005-005967-27-IT
Active, not recruiting
Not Applicable
Study pilot of metronomic chemotherapy with ciclofosfamide, celecoxib and desametasone in patients with diagnosis of carcinoma of the refractory ormon prostate in advanced stage appraisal pharmacodynamics - PROMET
AZIENDA USL 6 LIVORNO ZONA LIVORNESE0 sites27 target enrollmentFebruary 17, 2006
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- ORMONO REFRACTORY CARCINOMA OF PROSTATE IN ADVANCED STAGE
- Sponsor
- AZIENDA USL 6 LIVORNO ZONA LIVORNESE
- Enrollment
- 27
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with diagnosis of ormonorefrattario prostatico carcinoma in advanced phase \- ECOG PS 2 \- Attended of life at least 3 months \- Adapted renal functionality creatinina 1,25 x V.N. \- Adapted hepatic functionality bilirubina tot. 1,5 x V.N., SGOT and SGPT 3 xV.N., \- Adapted reservoir medullary GB 3000/mcl, PLT 100\.000/mcl, Hgb 10 g/dl. \- informed Consent written \- Suspension from at least 30 drug days antiandrogens with demonstration not answer of the PSA to the suspension
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) no
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •Scompensate metabolic diseases or serious infections in action \- cardiac Arrhythmies or ischemic cardiopathy and presence of whichever elevated cardiovascular risk \- Impossibility to execute adequate follow\-up \- Presence of sintomatic encefalic metastases \- a Presence of second neoplasia. \- gastroduodenal Presence of ulcera
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Metronomic chemotherapy in elderly non-fit patients with aggressive B-Cell lymphomas. Phase II studyB-Cell lymphomasMedDRA version: 21.0Level: LLTClassification code 10012855Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation)System Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2016-003703-62-ITFONDAZIONE ITALIANA LINFOMI ONLUS60
Active, not recruiting
Phase 1
Phase 2 trial evaluating metronomic chemotherapy in patients with relapsed or refractory Wilms tumorEUCTR2021-002540-67-FRCentre Oscar Lambret28
Recruiting
Not Applicable
A feasibility study of the metronomic chemotherapy using oral tegafur-uracil and cyclophosphamide for recurrent gynecological cancersadvance and recurrent gynecological cancerJPRN-UMIN000016438Saitama Medical University International Medical Center30
Active, not recruiting
Not Applicable
A phase II study evaluating the role of the combination of Vinorelbine,cyclophosphamide and capecitabine administered metronomically, that means low doses daily orally, in patients with advanced breast cancerMetastatic breast cancerMedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-024266-21-ITISTITUTO EUROPEO DI ONCOLOGIA100
Active, not recruiting
Not Applicable
A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with bevacizumab and erlotinib (BEXE), plus trastuzumab in HER2/neu positive tumors (BEXET), in advanced breast canceradvanced or metastatic breast cancerMedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2007-006025-27-ITISTITUTO EUROPEO DI ONCOLOGIA